Is There a New Pfizer COVID Vaccine? What to Know

Pfizer-BioNTech has been updating its COVID-19 vaccine roughly once a year to keep pace with new variants, much the way flu shots are reformulated each season. The most recent authorized formulation targeted the KP.2 variant lineage for the 2024–2025 season, and modeling is already underway for an LP.8.1-adapted formula for 2025–2026. So the short answer is yes, there is a newer version of the Pfizer vaccine available, and the process of refreshing it has become a recurring public-health routine rather than a one-time event.

How the Vaccine Gets Updated Each Year

The process for choosing which strain goes into the next COVID vaccine borrows heavily from the system that has guided flu vaccine updates for decades. The World Health Organization runs global surveillance to track which SARS-CoV-2 variants are circulating, how fast they are spreading, and how different they look to the immune system compared with earlier strains. Regulators then weigh immunologic, virologic, and molecular data before selecting a target strain for the upcoming season.¹ In practice, this means the FDA typically announces a recommended composition in the early summer, manufacturers produce updated doses, and the new shots reach pharmacies and clinics by early fall.

This annual cadence is relatively new. The original Pfizer vaccine launched in late 2020, targeting the ancestral Wuhan strain. In 2022, a bivalent formula combining the original strain with Omicron BA.4/BA.5 replaced it. By late 2023, that gave way to a monovalent XBB.1.5 shot, and in 2024, the formula shifted again to target KP.2. Each update reflected whichever variant family was dominant or rising at the time of the strain-selection decision.

What the Updated Formulas Are Designed to Do

Every update aims to close the gap between what your immune system recognizes and what the virus currently looks like. When researchers tested the XBB.1.5 monovalent booster in people who had not been recently infected, antibody levels against XBB.1.5 jumped roughly 27-fold, and responses against then-emerging subvariants like JN.1 rose 13- to 27-fold.² People who had also recovered from an Omicron infection before getting the updated booster showed the highest overall antibody levels against all tested variants. This kind of cross-neutralization is important because by the time a new formula reaches arms, the virus may have already drifted to a slightly different subvariant.

Researchers have also noted that updated vaccines reduce a phenomenon called immunological imprinting, where the immune system leans on its memory of the original strain rather than fully adapting to a new one. The XBB.1.5 booster still showed some imprinting, but far less than the earlier bivalent BA.5 formula had.² That improvement matters because it means the newer shots do a better job of training the immune system to recognize current threats rather than fighting the last war.

Real-World Protection Against Hospitalization

Antibody levels in a lab are encouraging, but what most people want to know is whether the updated vaccine actually keeps them out of the hospital. A large study in England compared the Pfizer BA.4-5 bivalent booster against hospitalization during the Omicron wave and found that protection peaked at about 56% in the first two weeks after vaccination, then gradually fell to around 38% after ten or more weeks.³ Those numbers may sound modest, but they represent additional protection layered on top of whatever immunity a person already carried from prior vaccination and infection.

Among older adults specifically, the picture is consistent. A real-world study found that those who received a fourth dose (bivalent booster) had a substantially lower rate of COVID-related hospitalization than those who stopped at three doses, with an adjusted hazard ratio of about 0.39, meaning the four-dose group’s risk was roughly 60% lower.⁴ Given that adults 65 and older account for a disproportionate share of hospitalizations and deaths, keeping up with booster doses has the most tangible payoff in this group.

Why Protection Fades and What Hybrid Immunity Means

One of the less intuitive things about COVID vaccines is that protection against infection drops faster than protection against severe disease. A study of children and adolescents in Japan found that vaccine-derived protection against infection faded to nearly zero within about ten months of the primary series, while protection against severe outcomes lasted longer.⁵ This pattern holds across age groups and is one reason health authorities moved to an annual update cycle: the infection-blocking effect wanes enough that a fresh dose keyed to the current variant provides a meaningful reset each fall.

If you have both been vaccinated and had a prior COVID infection, you carry what researchers call hybrid immunity. A systematic review found that hybrid immunity with a primary vaccine series was about 96% effective against hospitalization or severe disease at three months, and that figure barely budged at twelve months. Protection against reinfection was a different story, starting around 69% at three months and dropping to about 42% by a year.⁶ Adding a booster to hybrid immunity kept severe-disease protection similarly high, in the mid-to-upper 90s. The takeaway is that hybrid immunity is durable against the worst outcomes but still leaves you open to catching the virus again, which is part of why annual boosters remain relevant even if you have been infected before.

Common Side Effects of the Pfizer Vaccine

The side-effect profile of the Pfizer COVID vaccine has remained broadly consistent across formulations. In a study of 1,000 recipients, the most commonly reported reactions after the first dose were burning at the injection site (about 70%), fever (70%), pain at the injection site (63%), and muscle pain (63%). After the second dose, muscle pain was the most frequent complaint (63%), followed by rashes (61%) and injection-site pain (58%).⁷ These reactions are typical of what happens when your immune system mounts a response and are almost always short-lived, resolving within a day or two.

Later formulations, including the bivalent and updated monovalent boosters, have shown a similar pattern: mostly mild-to-moderate reactogenicity, with no new safety signals emerging. The consistency is partly a feature of the mRNA platform itself. Both Pfizer and Moderna vaccines encode a version of the spike protein using chemically modified mRNA wrapped in lipid nanoparticles. When the formula is updated to target a new variant, the delivery system stays the same; only the genetic instructions for the spike protein change. That means the body’s reaction to the shot itself does not change much from year to year.

Myocarditis Risk in Context

The rare link between mRNA COVID vaccines and myocarditis, an inflammation of the heart muscle, has been one of the most scrutinized safety signals in vaccine history. A large English study found that the risk of myocarditis was modestly elevated in the 28 days after a Pfizer dose, with incidence rate ratios of about 1.5 after a first or second dose and 1.7 after a booster. But the same study found that the risk after a positive COVID infection itself was far higher, with an incidence rate ratio above 11 in unvaccinated people and about 6 even in those who were vaccinated.⁸ The group at highest relative risk from the vaccine was young men, but even in that group, the absolute numbers remained small and were lower than the myocarditis risk from infection itself.

There is also reassuring evidence that booster doses do not compound the risk. An analysis of the U.S. vaccine safety reporting system found that the rate of myocarditis and pericarditis after booster doses was actually lower than after the primary two-dose series.⁹ A Nordic cohort study of adolescents and young adults confirmed the same trend: the myocarditis incidence rate ratio after a third Pfizer dose in males was about 2.2, compared with about 2.9 after the second dose.¹⁰ The Moderna vaccine carried a higher myocarditis signal than Pfizer across all studies, which is one reason some countries preferentially recommended Pfizer for younger men.

What About Children

The Pfizer vaccine for young children uses a much smaller dose than the adult version. In the original clinical trial for children aged six months to four years, a 3-microgram dose (one-tenth the adult dose) was given as a three-dose primary series. The vaccine was about 73% effective against symptomatic COVID starting seven days after the third dose. Side effects were mostly mild, with low fever rates that were similar between the vaccine group and the placebo group.¹¹

When the bivalent version (original plus BA.4/BA.5) was later tested as a fourth dose in children who had already completed the three-dose original series, it produced higher antibody levels against Omicron BA.4/BA.5 than the original formula had after the third dose, with no new safety concerns.¹² For parents weighing whether to get their young child the latest update, the pattern mirrors what we see in adults: the updated formula broadens and refreshes immune protection without introducing additional risk.

Immunocompromised People Need Extra Attention

If you are on immunosuppressive medication, have had an organ transplant, or are being treated for certain cancers, the vaccine still works for you but less reliably. A systematic review found that after two doses, only about a third of organ transplant recipients developed detectable antibodies, compared with nearly all healthy controls. People with blood cancers and autoimmune conditions on immunosuppressive therapy fared better but still lagged behind the general population.¹³ A third dose helped many non-responders seroconvert, though transplant recipients remained the most variable group.

Real-world effectiveness studies painted a broadly similar picture: vaccine effectiveness in immunocompromised populations ranged from about 64% to 90% against infection and 70% to 100% against severe illness, consistently lower than in the general population.¹⁴ This is why immunocompromised individuals were among the first groups recommended for additional doses and why staying current with each new formulation is particularly important for them. The gap in protection makes every percentage point of updated-vaccine effectiveness more consequential.

Getting the COVID Shot and the Flu Shot at the Same Time

A common practical question is whether you can roll up both sleeves (or the same sleeve twice) and get the COVID and flu vaccines in a single visit. The answer is yes. A study of healthcare workers who received a third Pfizer dose alongside an influenza vaccine found that the side-effect profile was similar to getting the shots separately, with no increase in adverse events from co-administration.¹⁵ Interestingly, the same study found that people who had a prior COVID infection before getting the booster reported more side effects than those who did not, regardless of whether the flu shot was given at the same time. So the flu shot is not the variable that matters; your prior infection history has more influence on how you feel afterward.

CDC guidance has consistently supported co-administration, and many pharmacies now offer both shots during the same appointment in the fall. There is no required waiting period between the two.

Timing After a Recent COVID Infection

If you just had COVID, you do not need to rush out for the updated vaccine the moment you recover. CDC guidance suggests you may consider waiting about three months from when your symptoms started or when you tested positive. Some experts recommend waiting four to six months after an infection or after your last vaccine dose before getting a booster, on the theory that your immune system already has a fresh response working and the booster will be more effective once that initial wave settles down.¹⁶ There is no hard cutoff that makes the vaccine unsafe to receive sooner; it is more about optimizing the immune response than avoiding harm.

Combination COVID-Flu Vaccines on the Horizon

Both Pfizer and Moderna are developing combination vaccines that would put COVID and influenza protection into a single shot. A review comparing the two companies’ approaches found that both candidates use mRNA technology and have shown strong immune responses and acceptable safety in trials. Moderna’s version, called mRNA-1083, produced somewhat stronger immune responses overall, while Pfizer’s candidate (mRNA-1020/1030) performed well but showed slightly lower effectiveness against influenza B strains.¹⁷ If either combination vaccine reaches the market, it could simplify the annual fall vaccination routine considerably and potentially improve uptake among people who find two separate appointments burdensome.

Why Fewer People Are Getting Each New Update

Despite ongoing updates, booster uptake has dropped sharply compared with the initial vaccine rollout. Research points to several overlapping reasons. One study found that willingness to receive an annual COVID booster was strongly associated with political party identification and trust in government, with those factors outweighing demographic variables like age.¹⁸ Message fatigue is another documented barrier: vaccinated individuals reported moderately high levels of fatigue with COVID-related health messaging, and that fatigue was linked to lower booster uptake even among people who had gotten earlier doses.¹⁹

There is some evidence that the availability of variant-adapted vaccines itself can partially counteract this fatigue. A study across Austria and Italy found that advertising an Omicron-adapted vaccine increased people’s stated willingness to get vaccinated, particularly among those who had already received three doses.²⁰ In other words, some people are not opposed to boosters in principle; they just need a reason to believe the new version is meaningfully different from what they already got. The same study found that even minor out-of-pocket costs could strongly reduce uptake, suggesting that keeping the updated vaccines free or low-cost matters as much as the messaging around them.

What a Cost-Effectiveness Model Projects for the Newest Formula

A recent modeling study estimated the potential impact of the upcoming LP.8.1-adapted Pfizer vaccine (the 2025–2026 formula) in U.S. adults. Without any vaccination, the model projected roughly 41.5 million symptomatic cases, about 338,000 hospitalizations, and nearly 44,000 deaths per season among adults, with people 65 and older bearing the heaviest burden: about 73% of hospitalizations and 83% of deaths. Vaccinating all adults 18 and older with the updated formula was projected to prevent over 620,000 cases, nearly 12,700 hospitalizations, and about 1,900 deaths per season.²¹ These are model projections, not guarantees, and the actual numbers will depend on which variant ends up dominating and how many people get the shot. But they illustrate why public-health planners continue to push for broad vaccination even years into the pandemic: the raw volume of preventable hospitalizations and deaths remains large, especially among older and high-risk adults.